<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">EMBO Rep</journal-id><journal-title-group><journal-title>EMBO Reports</journal-title></journal-title-group><issn pub-type="ppub">1469-221X</issn><issn pub-type="epub">1469-3178</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21415856</article-id><article-id pub-id-type="pmc">3077250</article-id><article-id pub-id-type="pii">embor201133</article-id><article-id pub-id-type="doi">10.1038/embor.2011.33</article-id><article-categories><subj-group subj-group-type="heading"><subject>Scientific Reports</subject></subj-group></article-categories><title-group><article-title>Ubiquitin-specific protease 4 is inhibited by its ubiquitin-like domain</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Luna-Vargas</surname><given-names>Mark P A</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Faesen</surname><given-names>Alex C</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>van Dijk</surname><given-names>Willem J</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rape</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fish</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sixma</surname><given-names>Titia K</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><aff id="a1"><label>1</label><institution>Division of Biochemistry and Center for Biomedical Genetics, The Netherlands Cancer Institute</institution>, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands</aff><aff id="a2"><label>2</label><institution>Department of Molecular and Cell Biology, University of California at Berkeley</institution>, Berkeley, California 94720, USA</aff></contrib-group><author-notes><corresp id="c1"><label>a</label>Tel:+31 20 512 1959; Fax: +31 20 512 1954; E-mail: <email>t.sixma@nki.nl</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>04</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>18</day><month>03</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>03</month><year>2011</year></pub-date><volume>12</volume><issue>4</issue><fpage>365</fpage><lpage>372</lpage><history><date date-type="received"><day>23</day><month>08</month><year>2010</year></date><date date-type="rev-recd"><day>21</day><month>01</month><year>2011</year></date><date date-type="accepted"><day>28</day><month>01</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011, European Molecular Biology Organization</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>European Molecular Biology Organization</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><!--author-paid--><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.</license-p></license></permissions><abstract abstract-type="hidden-editorial-summary"><title>Ubiquitin-specific protease 4 is inhibited by its ubiquitin-like domain</title><p>The ubiquitin-specific protease Usp4 contains an autoinhibitory Ubl domain in its catalytic domain. Inhibition can be relieved by interaction with a non-active USP, such as USP39.</p></abstract><abstract><p>USP4 is a member of the ubiquitin-specific protease (USP) family of deubiquitinating enzymes that has a role in spliceosome regulation. Here, we show that the crystal structure of the minimal catalytic domain of USP4 has the conserved USP-like fold with its typical ubiquitin-binding site. A ubiquitin-like (Ubl) domain inserted into the catalytic domain has autoregulatory function. This Ubl domain can bind to the catalytic domain and compete with the ubiquitin substrate, partially inhibiting USP4 activity against different substrates. Interestingly, other USPs, such as USP39, could relieve this inhibition.</p></abstract><kwd-group><kwd>regulation</kwd><kwd>structure</kwd><kwd>Ubl</kwd><kwd>USP4</kwd></kwd-group></article-meta></front><body><sec disp-level="1"><title>Introduction</title><p>Post-translational modification by the small, highly conserved ubiquitin (Ub) protein has an essential role in the regulation of many cellular processes in eukaryotes (<xref ref-type="bibr" rid="b20">Pickart, 2004</xref>; <xref ref-type="bibr" rid="b8">Hochstrasser, 2009</xref>). In this process, the carboxy-terminus of Ub forms an isopeptide with lysines on the target proteins, or on Ub itself, to form poly-Ub chains. The activity of the conjugating enzymes E1&#x02013;E2&#x02013;E3 is actively balanced through hydrolysis by deubiquitinating enzymes (DUBs; <xref ref-type="bibr" rid="b1">Amerik &#x00026; Hochstrasser, 2004</xref>; <xref ref-type="bibr" rid="b20">Pickart, 2004</xref>; <xref ref-type="bibr" rid="b19">Nijman et al, 2005</xref>; <xref ref-type="bibr" rid="b5">Deshaies &#x00026; Joazeiro, 2009</xref>; <xref ref-type="bibr" rid="b14">Komander et al, 2009</xref>). Deregulation of the ubiquitination pathway can lead to cancer and neurodegenerative diseases (<xref ref-type="bibr" rid="b9">Hoeller &#x00026; Dikic, 2009</xref>; <xref ref-type="bibr" rid="b16">Lopez-Otin &#x00026; Hunter, 2010</xref>).</p><p>More than 100 putative DUBs are known so far, belonging to five subfamilies of isopeptidases. The Ub-specific protease (USP) family is the largest, with more than 60 members in the human genome (<xref ref-type="bibr" rid="b21">Quesada et al, 2004</xref>; <xref ref-type="bibr" rid="b19">Nijman et al, 2005</xref>; <xref ref-type="bibr" rid="b14">Komander et al, 2009</xref>). USPs share a papain-like catalytic domain and crystal structures show a conserved catalytic core that undergoes conformational changes after Ub binding (<xref ref-type="bibr" rid="b10">Hu et al, 2002</xref>, <xref ref-type="bibr" rid="b11">2005</xref>; <xref ref-type="bibr" rid="b2">Avvakumov et al, 2006</xref>; <xref ref-type="bibr" rid="b23">Renatus et al, 2006</xref>; <xref ref-type="bibr" rid="b13">K&#x000f6;hler et al, 2010</xref>; <xref ref-type="bibr" rid="b25">Samara et al, 2010</xref>).</p><p>USPs are variable in size with modular domain architecture including, for example, TRAF-like, DUSP or Znf domains (<xref ref-type="bibr" rid="b19">Nijman et al, 2005</xref>; <xref ref-type="bibr" rid="b14">Komander et al, 2009</xref>). Sequence analysis predicted the presence of Ub-like (Ubl) domains in 17 different USPs (<xref ref-type="bibr" rid="b32">Zhu et al, 2007</xref>). Integrated Ubl domains are stretches of 45&#x02013;80 amino acids that share the &#x003b2;-grasp fold of Ub, but often have poor sequence conservation among subfamilies (<xref ref-type="bibr" rid="b12">Kiel &#x00026; Serrano, 2006</xref>; <xref ref-type="bibr" rid="b3">Burroughs et al, 2007</xref>). The Ubl domains in the USP family are located amino-terminally, within or C-terminally to the catalytic domain. Structural studies of the N-terminal Ubl domain of USP14 confirmed the Ubl-fold (Protein Data Bank (PDB): <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pdb" xlink:href="1WGG">1WGG</ext-link>) and showed involvement in proteasome binding that promotes the DUB activity of USP14 (<xref ref-type="bibr" rid="b11">Hu et al, 2005</xref>). Similar to USP14, USP4 has a Ubl domain N-terminal of its catalytic domain, but it has an additional Ubl domain embedded in the catalytic domain.</p><p>USP4 was previously known as ubiquitous nuclear protein (UNP) (<xref ref-type="bibr" rid="b7">Gupta et al, 1993</xref>). Identified as a proto-oncogene related to Tre 2/Tre 17 (USP6), USP4 shows a consistently elevated gene expression level in small cell tumours and lung adenocarcinomas, suggesting that it may have a possible causative role in neoplasia (<xref ref-type="bibr" rid="b6">Gray et al, 1995</xref>). Besides possible roles in Wnt signalling (<xref ref-type="bibr" rid="b31">Zhao et al, 2009</xref>) and recruitment to the A2A receptor (<xref ref-type="bibr" rid="b18">Milojevic et al, 2006</xref>), USP4 is recruited to the spliceosome by complex formation with Sart3 (<xref ref-type="bibr" rid="b26">Song et al, 2010</xref>). Here, it preferentially deubiquitinates K63-linked chains on the U4 component Prp3. Another component of the spliceosome complex is the catalytically inactive USP39 (<xref ref-type="bibr" rid="b27">Sowa et al, 2009</xref>; <xref ref-type="bibr" rid="b26">Song et al, 2010</xref>), which controls the messenger RNA levels of Aurora B (<xref ref-type="bibr" rid="b30">van Leuken et al, 2008</xref>).</p><p>Here, we report on the crystal structure of the catalytic domain of USP4 without the internal Ubl domain, and show how this Ubl domain acts as an autoregulatory domain that partially inhibits catalytic activity by competitive inhibition.</p></sec><sec disp-level="1"><title>Results</title><sec disp-level="2"><title>Identification of USP4&#x02013;D1D2</title><p>To gain insight into the structure and function of USP4, we expressed and purified the USP4 catalytic domain (amino acids 296&#x02013;954, <xref ref-type="fig" rid="f1">Fig 1A</xref>) in <italic>Escherichia coli</italic>. To improve the chances for crystallization, we used limited proteolysis. After treatment with thermolysin, two fragments&#x02014;domain 1 (D1) and 2 (D2)&#x02014;were obtained, which copurified on size exclusion chromatography and together retained DUB activity (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S1A,B</xref> online). We identified the composition of D1 and D2 using mass spectrometry and N-terminal sequencing (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S1C</xref> online) and compared them against a multi-sequence alignment of USP family members. This showed that the protease treatment removed an insertion between Leu 481 and Leu 766 (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S2</xref> online), yielding a minimal catalytic domain consisting of an enzymatically active complex of two fragments: USP4&#x02013;D1D2.</p></sec><sec disp-level="2"><title>Structure of the USP4&#x02013;D1D2 catalytic domain</title><p>We crystallized and determined the USP4&#x02013;D1D2 structure by molecular replacement using the USP8 catalytic domain (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pdb" xlink:href="2GFO">2GFO</ext-link>) as the search molecule, and refined it to 2.4 &#x000c5; resolution with an <italic>R</italic>/<italic>R</italic><sub>free</sub> of 0.178/0.21 and good geometry (<xref ref-type="fig" rid="f1">Fig 1B</xref>; <xref ref-type="supplementary-material" rid="S1">supplementary Table S1</xref> online). There are six molecules of USP4&#x02013;D1D2 per asymmetrical unit, with a pairwise root-mean-square deviation of approximately 0.7 &#x000c5; over 344 residues using the PISA program (<xref ref-type="bibr" rid="b15">Krissinel &#x00026; Henrick, 2004</xref>).</p><p>Similar to crystal structures of other USPs, the catalytic domain of USP4&#x02013;D1D2 resembles an extended right hand comprising three domains: Fingers, Thumb and Palm (<xref ref-type="fig" rid="f1">Fig 1B</xref>; <xref ref-type="supplementary-material" rid="S1">supplementary Fig S3</xref> online). The D1 fragment contains the Thumb domain and part of the Fingers domain with the Cys box (amino acids 303&#x02013;320) and QQD box (amino acids 390&#x02013;403) of the active site, whereas the D2 fragment completes the active site with the His box (amino acids 864&#x02013;885, 894&#x02013;903, 915&#x02013;922) and makes the remaining part of the Fingers and the Palm (<xref ref-type="bibr" rid="b21">Quesada et al, 2004</xref>; <xref ref-type="supplementary-material" rid="S1">supplementary Fig S2</xref> online). Like other USP structures (<xref ref-type="bibr" rid="b11">Hu et al, 2005</xref>; <xref ref-type="bibr" rid="b2">Avvakumov et al, 2006</xref>; <xref ref-type="bibr" rid="b23">Renatus et al, 2006</xref>; <xref ref-type="bibr" rid="b13">K&#x000f6;hler et al, 2010</xref>; <xref ref-type="bibr" rid="b25">Samara et al, 2010</xref>), except USP7 (<xref ref-type="bibr" rid="b10">Hu et al, 2002</xref>), the catalytic triad is in a catalytically competent configuration, wherein His 711-ND1 is 3.2 &#x000c5; away from Cys 311-SG and His 711-ND2 is hydrogen bonding with Asp 898-OD1 (2.7 &#x000c5;; <xref ref-type="fig" rid="f1">Fig 1B</xref>).</p><p>The zinc-finger ribbon observed in USP2 and USP8 is present in USP4 (<xref ref-type="fig" rid="f1">Fig 1B,C</xref>). The Zn<sup>2&#x0002b;</sup> ion brings together the D1 and D2 domains, tetrahedrally coordinated by cysteines on anti-parallel &#x003b2;-strands &#x003b2;1 and &#x003b2;2 in D1, and &#x003b2;4 in D2. This zinc-finger ribbon in the Fingers domain seems to be in the contracted &#x02018;closed-hand' configuration seen in USP8 that blocks access of Ub to its binding site (<xref ref-type="bibr" rid="b2">Avvakumov et al, 2006</xref>). A similar role was assigned to the two Ub-binding surface loops (BL1 and BL2) in USP14 (<xref ref-type="bibr" rid="b10">Hu et al, 2002</xref>) that block the active site, but relocate after Ub binding. In USP4, both loops (<xref ref-type="fig" rid="f1">Fig 1D</xref>)&#x02014;as well as a third blocking loop (BL3) that hinders access of the C-terminal tail of Ub to the binding pocket&#x02014;are observed.</p><p>Superposition of the six non-crystallographic symmetry-related molecules of USP4&#x02013;D1D2 shows that both the zinc-finger ribbon and the three blocking loops show flexibility (maximal C&#x003b1; displacement 4 &#x000c5;; <xref ref-type="fig" rid="f1">Fig 1C,D</xref>), which is in agreement with their role in activation (<xref ref-type="bibr" rid="b10">Hu et al, 2002</xref>; <xref ref-type="bibr" rid="b2">Avvakumov et al, 2006</xref>).</p></sec><sec disp-level="2"><title>The insert inhibits deubiquitinating activity</title><p>We compared the catalytic activity of the USP4 catalytic domain with and without the large insert, by using <italic>in vitro</italic> deubiquitinating assays. In these assays we followed the hydrolysis of K63- and K48-linked di-Ub into mono-Ub (<xref ref-type="fig" rid="f2">Fig 2A,B</xref>; <xref ref-type="supplementary-material" rid="S1">supplementary Fig S4A,B</xref> online). We observed that K63 di-Ub is more efficiently degraded than K48, in agreement with the role of USP4 in splicing (<xref ref-type="bibr" rid="b26">Song et al, 2010</xref>). Interestingly, quantification (<xref ref-type="fig" rid="f2">Fig 2D</xref>; <xref ref-type="supplementary-material" rid="S1">supplementary Fig S4D</xref> online) shows that USP4&#x02013;D1D2 without insert is more efficient at degrading both di-Ubs than the complete catalytic domain. When D1 and D2 are fused through a short linker, as found in USP7 (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S2</xref> online), their activity is similar to that of USP4&#x02013;D1D2, showing that the cause of the activation is the lack of insert and not the chain break (<xref ref-type="fig" rid="f2">Fig 2C</xref>; <xref ref-type="supplementary-material" rid="S1">supplementary Fig S4C</xref> online).</p><p>In Ub-7-amido-4-methylcoumarin (Ub-AMC) assays the intact USP4 catalytic domain is also less active than USP4&#x02013;D1D2 or the fusion protein. As only AMC is cleaved off, the inhibition is not dependent on the protein target. When analysed by Michaelis&#x02013;Menten kinetic analysis (<xref ref-type="fig" rid="f2">Fig 2E</xref>) the <italic>V</italic><sub>max</sub> values were similar, but the <italic>K</italic><sub>m</sub> for the intact catalytic domain (13.5 &#x003bc;M) was weaker than that for USP4&#x02013;D1D2 (0.20 &#x003bc;M), leading to approximately 90-fold lower catalytic efficiency overall (<italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub>) for USP4CD than for USP4&#x02013;D1D2.</p><p>As the insert seems to inhibit the DUB activity of USP4, we tested whether it could do so <italic>in trans</italic>. We expressed and purified the insert (amino acids 483&#x02013;765) and added it in increasing amounts to USP4&#x02013;D1D2 in the Ub-AMC assay (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S5A</xref> online). We observed that the insert slows deubiquitination by USP4&#x02013;D1D2. To investigate whether this reduction in DUB activity is due to molecular crowding, we repeated the <italic>in trans</italic> inhibition assay with USP4&#x02013;D1D2 in the presence of either SUMO or BSA (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S6</xref> online). Neither of these reduced DUB activity, confirming that the insert is intrinsically able to inhibit the catalytic activity of USP4.</p></sec><sec disp-level="2"><title>Competitive inhibition of the USP4 insert</title><p>We tested whether USP4&#x02013;D1D2 would directly interact with the insert. In a surface plasmon resonance (SPR; <xref ref-type="fig" rid="f3">Fig 3B</xref>) experiment, we observed binding of USP4&#x02013;D1D2 to the insert, with a <italic>K</italic><sub>d</sub> of 1.32 &#x003bc;M after equilibrium fitting. This affinity closely resembled the affinity of USP4&#x02013;D1D2 for Ub itself (<italic>K</italic><sub>d</sub> of 1.39 &#x003bc;M; <xref ref-type="fig" rid="f3">Fig 3A</xref>).</p><p>Therefore, we tested whether the insert could compete with Ub for binding to USP4&#x02013;D1D2, and would therefore bind to the same binding site. In an SPR competition experiment we flowed USP4&#x02013;D1D2 over a glutathione <italic>S</italic>-transferase (GST)-tagged insert in the presence of increasing amounts of Ub (<xref ref-type="fig" rid="f3">Fig 3D</xref>). We observed decreasing binding of USP4&#x02013;D1D2 to the GST-insert as the Ub concentration increased. The data could be fitted with a one-site competition binding model with a <italic>K</italic><sub>i</sub> of 1.4 &#x003bc;M, showing that the USP4 insert competes with Ub for binding to USP4&#x02013;D1D2.</p><p>Interestingly, the <italic>K</italic><sub>d</sub> of intact USP4CD for Ub is only fourfold less, compared to USP4&#x02013;D1D2 in an isothermal titration calorimetry (ITC) experiment (<xref ref-type="fig" rid="f3">Fig 3E</xref>). Although the exact <italic>K</italic><sub>d</sub>s are slightly tighter in the ITC experiment, qualitative analysis of SPR experiments agrees with this assessment. Non-specific binding at high concentrations precluded detailed fitting of these data (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S7</xref> online), but the curves show that binding of Ub to USP4CD has a slower off-rate than that of Ub to USP4&#x02013;D1D2, and together with the <italic>K</italic><sub>d</sub> value also suggest that it has a slower on-rate. As the <italic>K</italic><sub>m</sub> is dependent on <italic>K</italic><sub>d</sub> as well as the binding rate, the combination of slow kinetics and slightly lower affinity explains the differences in <italic>K</italic><sub>m</sub> values. Apparently, the insert prevents rapid binding as well as rapid release of the Ub substrate, allowing competitive binding.</p><p>Finally we analysed whether the enzymatic activity is competitively inhibited by the addition of the insert <italic>in trans.</italic> We tested the enzymatic activity with varying inhibitor concentrations against a range of substrate concentrations (<xref ref-type="fig" rid="f2">Fig 2F</xref>), and fitted the data against different inhibition models (<xref ref-type="bibr" rid="b4">Copeland, 2000</xref>). We found that the data were best explained by competitive inhibition with <italic>K</italic><sub>i</sub>=47 &#x003bc;M.</p><p>Although this value is lower than expected on the basis of the binding data alone, it explains why the USP4CD is not completely inhibited in the continuous presence of the insert. It seems that additional conformational changes take place. One possibility is that the enzyme reaches a state after turnover that has lower affinity for the insert, and is therefore not as effectively inhibited.</p></sec><sec disp-level="2"><title>The Ubl domain is sufficient for inhibition</title><p>The presence of a Ubl domain within the insert was predicted (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S2</xref> online; <xref ref-type="bibr" rid="b32">Zhu et al, 2007</xref>). To test whether the Ubl domain is sufficient for binding to the USP4 catalytic domain, we performed the SPR experiment with the purified Ubl domain (amino acids 483&#x02013;571, <xref ref-type="fig" rid="f1">Fig 1A</xref>) and found a <italic>K</italic><sub>d</sub> of 1.36 &#x003bc;M towards USP4&#x02013;D1D2, which is similar to that for the complete insert (<xref ref-type="fig" rid="f3">Fig 3C</xref>). This suggests that the Ubl domain is the functional part of the insert.</p><p>To test whether the Ubl domain can inhibit the DUB activity of USP4, we repeated the <italic>in trans</italic> inhibition assay with USP4&#x02013;D1D2 in the presence of increasing amounts of the Ubl domain (<xref ref-type="supplementary-material" rid="S1">supplementary Fig S6</xref> online) and found that it provides inhibition equal to the insert. We therefore conclude that the Ubl domain is sufficient to inhibit the DUB activity of USP4, through competitive inhibition of Ub binding.</p></sec><sec disp-level="2"><title>Regulation by other USP enzymes</title><p>As the Ubl domain seems to bind in the substrate Ub-binding site of USP4, we wondered whether other USP enzymes could also bind to the Ubl domain. We tested whether our Ubl domain containing insert could bind to the catalytic domain of USP39 and USP8, and found similarly high affinities as for USP4CD (<xref ref-type="fig" rid="f4">Fig 4B,C</xref>).</p><p>Then, we analysed whether these DUBs could modulate USP4CD activity. We repeated the <italic>in trans</italic> Ub-AMC assay with USP4CD in the presence of the intrinsically inactive USP39CD or an inactive variant of the USP8 catalytic domain, USP8CD-mut (<xref ref-type="fig" rid="f4">Fig 4A</xref>). For both USPs we observe a modest activation of USP4CD that was dependent on the presence of the Ubl-containing insert, as it does not increase the DUB activity of USP4&#x02013;D1D2 in this manner.</p><p>Apparently, other USP enzymes can regulate USP4 activity by competing for binding to the Ubl domain. This effect could be larger when the USPs have further interactions. As USP39 forms a stable complex with USP4 in cells (<xref ref-type="bibr" rid="b27">Sowa et al, 2009</xref>; <xref ref-type="bibr" rid="b26">Song et al, 2010</xref>), it is a prime candidate for an activating role <italic>in vivo</italic>.</p></sec></sec><sec disp-level="1"><title>Discussion</title><p>We show that the predicted Ubl domain within a large insert embedded in the USP4 catalytic domain partially inhibits DUB activity by competing with Ub for binding. Superposition of the crystal structure of USP4&#x02013;D1D2 and any Ubl domain on USP7 in complex with Ub-aldehyde (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pdb" xlink:href="1NBF">1NBF</ext-link>), respectively, shows that the Ubl domain would fit like a Ub molecule into the hand of USP4&#x02013;D1D2 (<xref ref-type="fig" rid="f5">Fig 5A</xref>), only requiring movements in the blocking loops and the zinc-finger ribbon. Hence, we propose a model in which the Ubl domain partially inhibits DUB activity through competitive inhibition by binding into the hand of USP4 and thus preventing Ub substrate binding (<xref ref-type="fig" rid="f5">Fig 5B</xref>).</p><p>This function of an integrated Ubl domain is relatively new. The Ubl domains in proteasomal shuttle factors Rad23 and Dsk2, as well as in Parkin and USP14, function in recruitment of ubiquitinated proteins to the proteasome (<xref ref-type="bibr" rid="b24">Sakata et al, 2003</xref>; <xref ref-type="bibr" rid="b11">Hu et al, 2005</xref>). Other Ubl domains regulate the enzymatic activities of immune-response inducible kinases such as IKK&#x003b2; (a subunit of I&#x003ba;B kinase complex; <xref ref-type="bibr" rid="b17">May et al, 2004</xref>), or as PB1 (Phox and Bem1) domains, have a role in the regulation of signal transduction in proteins such as P62, MEK5 and protein kinase C (<xref ref-type="bibr" rid="b29">Terasawa et al, 2001</xref>; <xref ref-type="bibr" rid="b28">Sumimoto et al, 2007</xref>). However, all these Ubl-domain families have low sequence similarities, indicating that their functions are probably distinct between subfamilies.</p><p>The activity of USPs is regulated through an inactive conformation of the catalytic triad, as in USP7, or through a series of blocking loops or a blocking zinc-finger ribbon. USP4 seems to combine the blocking loops and zinc-finger ribbon with a further regulation through the Ubl domain.</p><p>Whether Ubl domains provide a common regulation mechanism for the DUB activity of USPs is an interesting question for future research. A second Ubl domain is found within USP4, at its N-terminus. A recent crystal structure (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pdb" xlink:href="3JYU">3JYU</ext-link>, amino acids 139&#x02013;226) shows that this Ubl domain interacts extensively with the adjacent DUSP (domain in USP) domain (amino acids 27&#x02013;125). This region of the protein is primarily important for interaction with Sart3 (<xref ref-type="bibr" rid="b26">Song et al, 2010</xref>) and hence might not have this function.</p><p>However, USP4 is not the only DUB with a Ubl fold within its catalytic domain. Sequence analysis by <xref ref-type="bibr" rid="b32">Zhu et al (2007)</xref> identified an integrated Ubl fold within the catalytic domain of USPs 6, 11, 15, 19, 31, 32 and 43, embedded in a larger insert, like in USP4. In particular, USP11 and USP15 are closely related to USP4. This subgroup of USPs probably also regulates DUB activity through its Ubl domain.</p><p>The way in which Ubl-domain inhibition itself is regulated is an exciting question. One could imagine that further post-translational modification by, for example, phosphorylation or acetylation would enable the release of the full activity of the DUB enzyme. In addition, we have shown that binding partners such as USP39, can activate USP4 function by binding to the Ubl domain (<xref ref-type="fig" rid="f5">Fig 5C</xref>). Although the activation is modest (<xref ref-type="fig" rid="f4">Fig 4A</xref>), this could be increased by further interactions, as observed in the spliceosome complex.</p><p>Regardless of the mechanisms that regulate USP4 activation, it is clear that this type of internal regulation by a Ubl domain allows the creation of an extremely fast response element to external signals.</p></sec><sec disp-level="1" sec-type="methods"><title>Methods</title><p>For plasmids, cloning, protein preparation and identification, crystallization and structure determination procedures, see <xref ref-type="supplementary-material" rid="S1">supplementary information</xref> online and references.</p><p><bold>Ub-AMC assays.</bold> Quantitative activity (triplicate) and <italic>in trans</italic> inhibition (duplicate) assays or USP modulation assays (triplicate) were performed using Ub-AMC with 10 nM enzyme in 30 &#x003bc;l reaction volume in 384-well plates and preincubated for 15 min at 21&#x000b0; C, for inhibition assays with Ubl insert and with other DUBs for modulation assays. Initial velocities against Ub-AMC concentration were computed to derive steady-state kinetic parameters using GraphPad Prism5 (GraphPad Software Inc.). Non-linear fitting of four inhibition models was compared in GraphPad.</p><p><bold>Di-Ub assays.</bold> K48 and K63 di-Ub substrates were produced and purified as described (<xref ref-type="bibr" rid="b22">Raasi &#x00026; Pickart, 2005</xref>). 75 nM enzyme was incubated with 3 &#x003bc;M di-Ub, subjected to SDS&#x02013;polyacrylamide gel electrophoresis and image analysis, and quantitation was performed in duplicate with TINA 2.09 (Raytest Co.).</p><p><bold>SPR and ITC.</bold> SPR was performed on a Biacore T-100, with GST-Ub, GST-insert and GST-Ubl domain immobilized on anti-GST antibodies coupled to a CM5 chip. Data (duplicate) were processed using BiaEvaluation (GE Healthcare) and GraphPad Prism5. ITC was performed on a VP-ITC Micro Calorimeter (MicroCal, Inc.) by titrating Ub into USP4&#x02013;D1D2 or USP4CD.</p><p><bold>Accession number.</bold> <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="gen" xlink:href="2Y6E">2Y6E</ext-link>.</p><p><bold>Supplementary information</bold> is available at EMBO <italic>reports</italic> online (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.emboreports.org">http://www.emboreports.org</ext-link>).</p></sec><sec sec-type="supplementary-material" id="S1"><title>Supplementary Material</title><supplementary-material id="d31e30" content-type="local-data"><caption><title>Supplemental Data</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="embor201133s1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec></body><back><ack><p>We thank J. Lebbink for mass spectrometry, European Synchrotron Radiation Facility beamline scientists for assistance during X-ray data collection, A. Perrakis and P. Rucktooa for help with crystallographic analysis, R.G. Hibbert for help with SPR data analysis, and lab members for discussion and sharing of reagents. This study was supported by the European Union Network of Excellence project RUBICON and Dutch Cancer Society Project KWF 2008-4014.</p></ack><ref-list><ref id="b1"><mixed-citation publication-type="journal"><name><surname>Amerik</surname><given-names>AY</given-names></name>, <name><surname>Hochstrasser</surname><given-names>M</given-names></name> (<year>2004</year>) <article-title>Mechanism and function of deubiquitinating enzymes</article-title>. <source>Biochim Biophys Acta</source> <volume>1695</volume>: <fpage>189</fpage>&#x02013;<lpage>207</lpage><pub-id pub-id-type="pmid">15571815</pub-id></mixed-citation></ref><ref id="b2"><mixed-citation publication-type="journal"><name><surname>Avvakumov</surname><given-names>GV</given-names></name>, <name><surname>Walker</surname><given-names>JR</given-names></name>, <name><surname>Xue</surname><given-names>S</given-names></name>, <name><surname>Finerty</surname><given-names>PJ</given-names><suffix>Jr</suffix></name>, <name><surname>Mackenzie</surname><given-names>F</given-names></name>, <name><surname>Newman</surname><given-names>EM</given-names></name>, <name><surname>Dhe-Paganon</surname><given-names>S</given-names></name> (<year>2006</year>) <article-title>Amino-terminal dimerization, NRDP1&#x02013;rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8)</article-title>. <source>J Biol Chem</source> <volume>281</volume>: <fpage>38061</fpage>&#x02013;<lpage>38070</lpage><pub-id pub-id-type="pmid">17035239</pub-id></mixed-citation></ref><ref id="b3"><mixed-citation publication-type="journal"><name><surname>Burroughs</surname><given-names>AM</given-names></name>, <name><surname>Balaji</surname><given-names>S</given-names></name>, <name><surname>Iyer</surname><given-names>LM</given-names></name>, <name><surname>Aravind</surname><given-names>L</given-names></name> (<year>2007</year>) <article-title>Small but versatile: the extraordinary functional and structural diversity of the &#x003b2;-grasp fold</article-title>. <source>Biol Direct</source> <volume>2</volume>: <fpage>18</fpage><pub-id pub-id-type="pmid">17605815</pub-id></mixed-citation></ref><ref id="b4"><mixed-citation publication-type="journal"><name><surname>Copeland</surname><given-names>RA</given-names></name> (<year>2000</year>) <source>Enzymes: A Practical Introduction to Structure, Mechanism and Data Analysis</source>, pp <fpage>270</fpage>&#x02013;<lpage>290</lpage>, UK: Wiley</mixed-citation></ref><ref id="b5"><mixed-citation publication-type="journal"><name><surname>Deshaies</surname><given-names>RJ</given-names></name>, <name><surname>Joazeiro</surname><given-names>CA</given-names></name> (<year>2009</year>) <article-title>RING domain E3 ubiquitin ligases</article-title>. <source>Annu Rev Biochem</source> <volume>78</volume>: <fpage>399</fpage>&#x02013;<lpage>434</lpage><pub-id pub-id-type="pmid">19489725</pub-id></mixed-citation></ref><ref id="b6"><mixed-citation publication-type="journal"><name><surname>Gray</surname><given-names>DA</given-names></name>, <name><surname>Inazawa</surname><given-names>J</given-names></name>, <name><surname>Gupta</surname><given-names>K</given-names></name>, <name><surname>Wong</surname><given-names>A</given-names></name>, <name><surname>Ueda</surname><given-names>R</given-names></name>, <name><surname>Takahashi</surname><given-names>T</given-names></name> (<year>1995</year>) <article-title>Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung tumors</article-title>. <source>Oncogene</source> <volume>10</volume>: <fpage>2179</fpage>&#x02013;<lpage>2183</lpage><pub-id pub-id-type="pmid">7784062</pub-id></mixed-citation></ref><ref id="b7"><mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>K</given-names></name>, <name><surname>Copeland</surname><given-names>NG</given-names></name>, <name><surname>Gilbert</surname><given-names>DJ</given-names></name>, <name><surname>Jenkins</surname><given-names>NA</given-names></name>, <name><surname>Gray</surname><given-names>DA</given-names></name> (<year>1993</year>) <article-title><italic>Unp</italic>, a mouse gene related to the <italic>tre</italic> oncogene</article-title>. <source>Oncogene</source> <volume>8</volume>: <fpage>2307</fpage>&#x02013;<lpage>2310</lpage><pub-id pub-id-type="pmid">8336951</pub-id></mixed-citation></ref><ref id="b8"><mixed-citation publication-type="journal"><name><surname>Hochstrasser</surname><given-names>M</given-names></name> (<year>2009</year>) <article-title>Origin and function of ubiquitin-like proteins</article-title>. <source>Nature</source> <volume>458</volume>: <fpage>422</fpage>&#x02013;<lpage>429</lpage><pub-id pub-id-type="pmid">19325621</pub-id></mixed-citation></ref><ref id="b9"><mixed-citation publication-type="journal"><name><surname>Hoeller</surname><given-names>D</given-names></name>, <name><surname>Dikic</surname><given-names>I</given-names></name> (<year>2009</year>) <article-title>Targeting the ubiquitin system in cancer therapy</article-title>. <source>Nature</source> <volume>456</volume>: <fpage>438</fpage>&#x02013;<lpage>444</lpage><pub-id pub-id-type="pmid">19325623</pub-id></mixed-citation></ref><ref id="b10"><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>M</given-names></name>, <name><surname>Li</surname><given-names>P</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Yao</surname><given-names>T</given-names></name>, <name><surname>Wu</surname><given-names>JW</given-names></name>, <name><surname>Gu</surname><given-names>W</given-names></name>, <name><surname>Cohen</surname><given-names>RE</given-names></name>, <name><surname>Shi</surname><given-names>Y</given-names></name> (<year>2002</year>) <article-title>Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde</article-title>. <source>Cell</source> <volume>111</volume>: <fpage>1041</fpage>&#x02013;<lpage>1054</lpage><pub-id pub-id-type="pmid">12507430</pub-id></mixed-citation></ref><ref id="b11"><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>M</given-names></name>, <name><surname>Li</surname><given-names>P</given-names></name>, <name><surname>Song</surname><given-names>L</given-names></name>, <name><surname>Jeffrey</surname><given-names>PD</given-names></name>, <name><surname>Chenova</surname><given-names>TA</given-names></name>, <name><surname>Wilkinson</surname><given-names>KD</given-names></name>, <name><surname>Cohen</surname><given-names>RE</given-names></name>, <name><surname>Shi</surname><given-names>Y</given-names></name> (<year>2005</year>) <article-title>Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14</article-title>. <source>EMBO J</source> <volume>24</volume>: <fpage>3747</fpage>&#x02013;<lpage>3756</lpage><pub-id pub-id-type="pmid">16211010</pub-id></mixed-citation></ref><ref id="b12"><mixed-citation publication-type="journal"><name><surname>Kiel</surname><given-names>C</given-names></name>, <name><surname>Serrano</surname><given-names>L</given-names></name> (<year>2006</year>) <article-title>The ubiquitin domain superfold: structure-based sequence alignments and characterization of binding epitopes</article-title>. <source>J Mol Biol</source> <volume>355</volume>: <fpage>821</fpage>&#x02013;<lpage>844</lpage><pub-id pub-id-type="pmid">16310215</pub-id></mixed-citation></ref><ref id="b13"><mixed-citation publication-type="journal"><name><surname>K&#x000f6;hler</surname><given-names>A</given-names></name>, <name><surname>Zimmerman</surname><given-names>E</given-names></name>, <name><surname>Schneider</surname><given-names>M</given-names></name>, <name><surname>Hurt</surname><given-names>E</given-names></name>, <name><surname>Zheng</surname><given-names>N</given-names></name> (<year>2010</year>) <article-title>Structural basis for assembly and activation of the heterotetrameric SAGA histone H2B deubiquitinase module</article-title>. <source>Cell</source> <volume>141</volume>: <fpage>606</fpage>&#x02013;<lpage>617</lpage><pub-id pub-id-type="pmid">20434206</pub-id></mixed-citation></ref><ref id="b14"><mixed-citation publication-type="journal"><name><surname>Komander</surname><given-names>D</given-names></name>, <name><surname>Clague</surname><given-names>MJ</given-names></name>, <name><surname>Urbe</surname><given-names>S</given-names></name> (<year>2009</year>) <article-title>Breaking the chains: structure and function of the deubiquitinases</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>10</volume>: <fpage>550</fpage>&#x02013;<lpage>563</lpage><pub-id pub-id-type="pmid">19626045</pub-id></mixed-citation></ref><ref id="b15"><mixed-citation publication-type="journal"><name><surname>Krissinel</surname><given-names>E</given-names></name>, <name><surname>Henrick</surname><given-names>K</given-names></name> (<year>2004</year>) <article-title>Secondary-structure matching (ssm), a new tool for fast protein structure alignment in three dimensions</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source> <volume>60</volume>: <fpage>2256</fpage>&#x02013;<lpage>2268</lpage><pub-id pub-id-type="pmid">15572779</pub-id></mixed-citation></ref><ref id="b16"><mixed-citation publication-type="journal"><name><surname>Lopez-Otin</surname><given-names>C</given-names></name>, <name><surname>Hunter</surname><given-names>T</given-names></name> (<year>2010</year>) <article-title>The regulatory crosstalk between kinases and proteases in cancer</article-title>. <source>Nat Rev Cancer</source> <volume>10</volume>: <fpage>278</fpage>&#x02013;<lpage>292</lpage><pub-id pub-id-type="pmid">20300104</pub-id></mixed-citation></ref><ref id="b17"><mixed-citation publication-type="journal"><name><surname>May</surname><given-names>MJ</given-names></name>, <name><surname>Larsen</surname><given-names>SE</given-names></name>, <name><surname>Shim</surname><given-names>JH</given-names></name>, <name><surname>Madge</surname><given-names>LA</given-names></name>, <name><surname>Ghosh</surname><given-names>S</given-names></name> (<year>2004</year>) <article-title>A novel ubiquitin-like domain in I&#x003ba;B kinase &#x003b2; is required for functional activity of the kinase</article-title>. <source>J Biol Chem</source> <volume>279</volume>: <fpage>45528</fpage>&#x02013;<lpage>45539</lpage><pub-id pub-id-type="pmid">15319427</pub-id></mixed-citation></ref><ref id="b18"><mixed-citation publication-type="journal"><name><surname>Milojevic</surname><given-names>T</given-names></name>, <name><surname>Reiterer</surname><given-names>V</given-names></name>, <name><surname>Stefan</surname><given-names>E</given-names></name>, <name><surname>Korkhov</surname><given-names>VM</given-names></name>, <name><surname>Dorostkar</surname><given-names>MM</given-names></name>, <name><surname>Ducza</surname><given-names>E</given-names></name>, <name><surname>Ogris</surname><given-names>E</given-names></name>, <name><surname>Boehm</surname><given-names>S</given-names></name>, <name><surname>Freissmuth</surname><given-names>M</given-names></name>, <name><surname>Nanoff</surname><given-names>C</given-names></name> (<year>2006</year>) <article-title>The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor</article-title>. <source>Mol Pharmacol</source> <volume>69</volume>: <fpage>1083</fpage>&#x02013;<lpage>1094</lpage><pub-id pub-id-type="pmid">16339847</pub-id></mixed-citation></ref><ref id="b19"><mixed-citation publication-type="journal"><name><surname>Nijman</surname><given-names>SM</given-names></name>, <name><surname>Luna-Vargas</surname><given-names>MP</given-names></name>, <name><surname>Velds</surname><given-names>A</given-names></name>, <name><surname>Brummelkamp</surname><given-names>TR</given-names></name>, <name><surname>Dirac</surname><given-names>AM</given-names></name>, <name><surname>Sixma</surname><given-names>TK</given-names></name>, <name><surname>Bernards</surname><given-names>R</given-names></name> (<year>2005</year>) <article-title>A genomic and functional inventory of deubiquitinating enzymes</article-title>. <source>Cell</source> <volume>123</volume>: <fpage>773</fpage>&#x02013;<lpage>786</lpage><pub-id pub-id-type="pmid">16325574</pub-id></mixed-citation></ref><ref id="b20"><mixed-citation publication-type="journal"><name><surname>Pickart</surname><given-names>CM</given-names></name> (<year>2004</year>) <article-title>Back to the future with ubiquitin</article-title>. <source>Cell</source> <volume>116</volume>: <fpage>181</fpage>&#x02013;<lpage>190</lpage><pub-id pub-id-type="pmid">14744430</pub-id></mixed-citation></ref><ref id="b21"><mixed-citation publication-type="journal"><name><surname>Quesada</surname><given-names>V</given-names></name>, <name><surname>Diaz-Perales</surname><given-names>A</given-names></name>, <name><surname>Gutierrez-Fernandez</surname><given-names>A</given-names></name>, <name><surname>Garabaya</surname><given-names>C</given-names></name>, <name><surname>Cal</surname><given-names>S</given-names></name>, <name><surname>Lopez-Otin</surname><given-names>C</given-names></name> (<year>2004</year>) <article-title>Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases</article-title>. <source>Biochem Biophys Res Commun</source> <volume>314</volume>: <fpage>54</fpage>&#x02013;<lpage>62</lpage><pub-id pub-id-type="pmid">14715245</pub-id></mixed-citation></ref><ref id="b22"><mixed-citation publication-type="journal"><name><surname>Raasi</surname><given-names>S</given-names></name>, <name><surname>Pickart</surname><given-names>CM</given-names></name> (<year>2005</year>) <article-title>Ubiquitin chains synthesis</article-title>. <source>Methods Mol Biol</source> <volume>301</volume>: <fpage>47</fpage>&#x02013;<lpage>55</lpage><pub-id pub-id-type="pmid">15917625</pub-id></mixed-citation></ref><ref id="b23"><mixed-citation publication-type="journal"><name><surname>Renatus</surname><given-names>M</given-names></name> <etal/> (<year>2006</year>) <article-title>Structural basis of ubiquitin recognition by the deubiquitinating protease USP2</article-title>. <source>Structure</source> <volume>14</volume>: <fpage>1293</fpage>&#x02013;<lpage>1302</lpage><pub-id pub-id-type="pmid">16905103</pub-id></mixed-citation></ref><ref id="b24"><mixed-citation publication-type="journal"><name><surname>Sakata</surname><given-names>E</given-names></name> <etal/> (<year>2003</year>) <article-title>Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain</article-title>. <source>EMBO Rep</source> <volume>4</volume>: <fpage>301</fpage>&#x02013;<lpage>306</lpage><pub-id pub-id-type="pmid">12634850</pub-id></mixed-citation></ref><ref id="b25"><mixed-citation publication-type="journal"><name><surname>Samara</surname><given-names>NL</given-names></name>, <name><surname>Datta</surname><given-names>AB</given-names></name>, <name><surname>Berndsen</surname><given-names>CE</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Yao</surname><given-names>T</given-names></name>, <name><surname>Cohen</surname><given-names>RE</given-names></name>, <name><surname>Wolberger</surname><given-names>C</given-names></name> (<year>2010</year>) <article-title>Structural insights into the assembly and function of the SAGA deubiquitinating module</article-title>. <source>Science</source> <volume>328</volume>: <fpage>1025</fpage>&#x02013;<lpage>1029</lpage><pub-id pub-id-type="pmid">20395473</pub-id></mixed-citation></ref><ref id="b26"><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>EJ</given-names></name>, <name><surname>Werner</surname><given-names>SL</given-names></name>, <name><surname>Neubauer</surname><given-names>J</given-names></name>, <name><surname>Stegmeier</surname><given-names>F</given-names></name>, <name><surname>Aspden</surname><given-names>J</given-names></name>, <name><surname>Rio</surname><given-names>D</given-names></name>, <name><surname>Harper</surname><given-names>JW</given-names></name>, <name><surname>Elledge</surname><given-names>SJ</given-names></name>, <name><surname>Kirschner</surname><given-names>MW</given-names></name>, <name><surname>Rape</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>The Prp19 complex and the Usp4<sup>Sart3</sup> deubiquitinating enzyme control reversible ubiquitination at the spliceosome</article-title>. <source>Genes Dev</source> <volume>24</volume>: <fpage>1434</fpage>&#x02013;<lpage>1447</lpage><pub-id pub-id-type="pmid">20595234</pub-id></mixed-citation></ref><ref id="b27"><mixed-citation publication-type="journal"><name><surname>Sowa</surname><given-names>ME</given-names></name>, <name><surname>Bennett</surname><given-names>EJ</given-names></name>, <name><surname>Gygi</surname><given-names>SP</given-names></name>, <name><surname>Harper</surname><given-names>JW</given-names></name> (<year>2009</year>) <article-title>Defining the human deubiquitinating enzyme interaction landscape</article-title>. <source>Cell</source> <volume>138</volume>: <fpage>389</fpage>&#x02013;<lpage>403</lpage><pub-id pub-id-type="pmid">19615732</pub-id></mixed-citation></ref><ref id="b28"><mixed-citation publication-type="journal"><name><surname>Sumimoto</surname><given-names>H</given-names></name>, <name><surname>Kamakura</surname><given-names>S</given-names></name>, <name><surname>Ito</surname><given-names>T</given-names></name> (<year>2007</year>) <article-title>Structure and function of the PB1 domain, a protein interaction module conserved in animals, fungi, amoebas, and plants</article-title>. <source>Sci STKE</source> <volume>2007</volume>: <fpage>re6</fpage><pub-id pub-id-type="pmid">17726178</pub-id></mixed-citation></ref><ref id="b29"><mixed-citation publication-type="journal"><name><surname>Terasawa</surname><given-names>H</given-names></name>, <name><surname>Noda</surname><given-names>Y</given-names></name>, <name><surname>Ito</surname><given-names>T</given-names></name>, <name><surname>Hatanaka</surname><given-names>H</given-names></name>, <name><surname>Ichikawa</surname><given-names>S</given-names></name>, <name><surname>Ogura</surname><given-names>K</given-names></name>, <name><surname>Sumimoto</surname><given-names>H</given-names></name>, <name><surname>Inagaki</surname><given-names>F</given-names></name> (<year>2001</year>) <article-title>Structure and ligand recognition of the PB1 domain: a novel protein module binding to the PC motif</article-title>. <source>EMBO J</source> <volume>20</volume>: <fpage>3947</fpage>&#x02013;<lpage>3956</lpage><pub-id pub-id-type="pmid">11483498</pub-id></mixed-citation></ref><ref id="b30"><mixed-citation publication-type="journal"><name><surname>van Leuken</surname><given-names>RJ</given-names></name>, <name><surname>Luna-Vargas</surname><given-names>MP</given-names></name>, <name><surname>Sixma</surname><given-names>TK</given-names></name>, <name><surname>Wolthuis</surname><given-names>RM</given-names></name>, <name><surname>Medema</surname><given-names>RH</given-names></name> (<year>2008</year>) <article-title>Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B</article-title>. <source>Cell Cycle</source> <volume>7</volume>: <fpage>2710</fpage>&#x02013;<lpage>2719</lpage><pub-id pub-id-type="pmid">18728397</pub-id></mixed-citation></ref><ref id="b31"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>B</given-names></name>, <name><surname>Schlesiger</surname><given-names>C</given-names></name>, <name><surname>Masucci</surname><given-names>MG</given-names></name>, <name><surname>Lindsten</surname><given-names>K</given-names></name> (<year>2009</year>) <article-title>The ubiquitin specific protease 4 (Usp4) is a new player in the Wnt signaling pathway</article-title>. <source>J Cell Mol Med</source> <volume>13</volume>: <fpage>1886</fpage>&#x02013;<lpage>1895</lpage><pub-id pub-id-type="pmid">20141612</pub-id></mixed-citation></ref><ref id="b32"><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>X</given-names></name>, <name><surname>Menard</surname><given-names>R</given-names></name>, <name><surname>Sulea</surname><given-names>T</given-names></name> (<year>2007</year>) <article-title>High incidence of ubiquitin-like domains in human ubiquitin-specific proteases</article-title>. <source>Proteins</source> <volume>69</volume>: <fpage>1</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">17597129</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that they have no conflict of interest.</p></fn></fn-group></back><floats-group><fig id="f1"><label>Figure 1</label><caption><p>The catalytic domain of USP4&#x02013;D1D2. (<bold>A</bold>) Domain architecture of USP4 and fragments expressed. (<bold>B</bold>) Crystal structure of USP4&#x02013;D1D2 catalytic domain in cartoon representation, with secondary structure elements labelled. D1 and D2 are coloured as in (<bold>A</bold>). Catalytic triad and the cysteines (yellow) coordinating zinc (grey sphere) are shown in stick representation. (<bold>C</bold>, <bold>D</bold>) Superposition of six non-crystallographic symmetry-related copies in the asymmetric unit showing flexibility in (<bold>C</bold>) the zinc-finger ribbon and (<bold>D</bold>) blocking loops, BL1&#x02013;3. Ub, ubiquitin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="embor201133f1"/></fig><fig id="f2"><label>Figure 2</label><caption><p>Insert inhibits the DUB activity of USP4CD. (<bold>A</bold>&#x02013;<bold>C</bold>) The full-length USP4 catalytic domain (<bold>A</bold>) is much less active than (<bold>B</bold>) USP4&#x02013;D1D2 or (<bold>C</bold>) USP4 fusion in deubiquitinating K63 di-Ub (Coomassie-stained SDS&#x02013;PAGE gels). (<bold>D</bold>) Quantification of mono-Ub in K63 di-Ub cleavage assays. The intensity of the mono-Ub band is plotted against time. (<bold>E</bold>) The inhibitory effect of the insert is observed in a Ub-AMC assay. On comparing <italic>K</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub> between USP4CD and D1D2, we observed a 90 times lower enzyme efficiency for the insert containing USP4CD. (<bold>F</bold>) Inhibition of USP4&#x02013;D1D2 <italic>in trans</italic> in Ub-AMC assays at different Ubl-insert concentrations (5, 15, 45 and 90 &#x003bc;M) can be jointly fit as a competitive inhibitor. SDS&#x02013;PAGE, SDS&#x02013;polyacrylamide gel electrophoresis; Ub, ubiquitin; Ub-AMC, ubiquitin-7-amido-4-methylcoumarin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="embor201133f2"/></fig><fig id="f3"><label>Figure 3</label><caption><p>Ubiquitin competes with the insert or Ubl-domain for binding to USP4&#x02013;D1D2. (<bold>A</bold>&#x02013;<bold>C</bold>) Interaction of Ub and the insert fragments with USP4&#x02013;D1D2 was studied by SPR experiments. Top: (<bold>A</bold>) GST-tagged Ub, (<bold>B</bold>) GST-insert and (<bold>C</bold>) GST-Ubl domain were immobilized on anti-GST antibodies coupled to a CM5 Biacore chip and USP4&#x02013;D1D2 was flowed over the chip at different concentrations. Bottom: Langmuir binding curves. (<bold>D</bold>) Competition experiment with immobilized GST insert on USP4&#x02013;D1D2 with varying concentrations of Ub. A one-site competition binding model was fitted (<italic>K</italic><sub>i</sub>=1.4 &#x003bc;M). (<bold>E</bold>) The interaction of Ub with USP4&#x02013;D1D2 (left) and with full-length USP4CD (right) were studied by ITC. Thermodynamic values for USP4&#x02013;D1D2 (&#x00394;<italic>H</italic>=&#x02212;14.3 kcal/mol and &#x00394;<italic>S</italic>=&#x02212;16.9 cal/mol/deg), for USP4CD (&#x00394;<italic>H</italic>=&#x02212;11.4 kcal/mol and &#x00394;<italic>S</italic>=&#x02212;10.0 cal/mol/deg). GST, glutathione <italic>S</italic>-transferase; ITC, isothermal titration calorimetry; Ub, ubiquitin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="embor201133f3"/></fig><fig id="f4"><label>Figure 4</label><caption><p>USP39CD binds to the Ubl domain and increases the deubiquitinating-enzyme activity of USP4CD. (<bold>A</bold>) Other USPs activate the DUB activity of USP4CD <italic>in trans</italic> in a Ub-AMC assay (USP39CD: 10, 20, 50, 100, 500 and 1,000 nM; USP8CD-mut: 1,000 nM). (<bold>B</bold>) USP39 and (<bold>C</bold>) USP8-mut bind to Ubl insert, in an SPR assay analogous to <xref ref-type="fig" rid="f2">Fig 2B</xref>. DUB, deubiquitinating enzyme; GST, glutathione-<italic>S</italic>-transferase; mut, mutant; Ub, ubiquitin; Ub-AMC, ubiquitin-7-amido-4-methylcoumarin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="embor201133f4"/></fig><fig id="f5"><label>Figure 5</label><caption><p>Model for Ubl domain inhibition on USP4. (<bold>A</bold>) Structural model in which interaction of the Ubl domain with USP4CD inhibits the binding of Ub. (<bold>B</bold>) Schematic model of the auto-inhibitory role of the Ubl domain in USP4. (<bold>C</bold>) Other USP enzymes, such as USP39, may relieve the inhibition by binding to the Ubl domain. Ub, ubiquitin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="embor201133f5"/></fig></floats-group></article>